AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

MLTX · NASDAQ · Biotechnology

MoonLake Immunotherapeutics (MLTX)

Develops sonelokimab for inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis.

$12.78

vs last close−0.60 (−4.47%)

MoonLake Immunotherapeutics Target of Unusually High Options Trading (NASDAQ:MLTX)
Defense WorldAug 11
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
ReutersAug 10
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
GlobeNewsWireAug 10
Arrowstreet Capital Limited Partnership Acquires New Shares in MoonLake Immunotherapeutics $MLTX
Defense WorldAug 6
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
Zacks Investment ResearchJul 31
MoonLake Immunotherapeutics' CFO Sells 39K Shares
Fool - Investing NewsJul 3
MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion
Seeking AlphaJun 26
MoonLake Immunotherapeutics: Label Upside Drives The Next Leg Higher
Seeking AlphaJun 23
MoonLake Immunotherapeutics Announces Proposed Public Offering
GlobeNewsWireJun 22
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
Seeking AlphaJun 22
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
GlobeNewsWireJun 21
FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars
BenzingaMay 11
MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket
Investors Business DailyMay 11
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
GlobeNewsWireMay 10
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
The Motley FoolApr 18
Da Silva Jorge Santos Sells 98,127 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock
Defense WorldApr 16
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 6% – Should You Sell?
Defense WorldApr 12
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
The Motley FoolApr 7
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
GlobeNewsWireMar 28
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade
Defense WorldMar 20
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
The Motley FoolMar 16
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX
Defense WorldMar 14
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Hold” from Analysts
Defense WorldMar 13
MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal
Seeking AlphaFeb 24